Dermatitis Herpetiformis and Linear IgA Bullous Dermatosis

Published on 05/03/2015 by admin

Filed under Dermatology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 2566 times

25

Dermatitis Herpetiformis and Linear IgA Bullous Dermatosis

This is the third chapter, along with Chapters 23 and 24, that deals with autoimmune bullous diseases (see Table 23.1).

Dermatitis Herpetiformis (DH)

Autoimmune bullous disease that is a cutaneous manifestation of celiac disease, with >90% of patients having histologic evidence of some degree of gluten-sensitive enteropathy; ~20% of patients with DH have symptomatic celiac disease.

In predisposed individuals (e.g. those with HLA-DQ2), IgA antibodies form against gliadin cross-linked to tissue tranglutaminase; the presumed autoantigen in the skin is epidermal transglutaminase (Fig. 25.1).

image

Fig. 25.1 Proposed pathogenesis of dermatitis herpetiformis and celiac disease. A Dietary wheat, barley, or rye is processed by digestive enzymes into antigenic gliadin peptides, which are transported intact across the mucosal epithelium. Within the lamina propria, tissue transglutaminase (TG2) (1) deamidates glutamine residues within gliadin peptides to glutamic acid and (2) becomes covalently cross-linked to gliadin peptides via isopeptidyl bonds (formed between gliadin glutamine and TG2 lysine residues). B CD4+ T cells in the lamina propria recognize deamidated gliadin peptides presented by HLA-DQ2 or -DQ8 molecules on antigen-presenting cells, resulting in the production of Th1 cytokines and matrix metalloproteinases that cause mucosal epithelial cell damage and tissue remodeling. In addition, TG2-specific B cells take up TG2–gliadin complexes and present gliadin peptides to gliadin-specific helper T cells, which stimulate the B cells to produce IgA anti-TG2. C Over time, IgA directed against TG3 (IgA anti-TG3) forms as a result of epitope spreading and both IgA anti-TG2 and IgA anti-TG3 circulate in the bloodstream. D When IgA anti-TG3 antibodies reach the dermis, they complex with TG3 antigens which have been produced by keratinocytes (epidermal TG) and then have diffused into the dermis. That is, IgA/TG3 immune complexes are formed locally within the papillary dermis. This leads to neutrophil chemotaxis (with formation of neutrophilic abscesses), proteolytic cleavage of the lamina lucida, and subepidermal blister formation.

Primary lesions consist of pruritic vesicles on an erythematous base and edematous erythematous papules that are often grouped (i.e. herpetiform); however, due to scratching, only excoriated papules and hemorrhagic crusts may be present (Fig. 25.2).

Favored sites of involvement are the elbows, extensor forearms, knees, posterior neck, and presacral/buttock region, with lesions in a symmetric distribution pattern.

Histologically, collections of neutrophils are seen within the dermal papillae of involved skin; by direct immunofluorescence (DIF), granular deposits of IgA are detected within dermal papillae of adjacent, normal-appearing skin in at least 90% of patients (see Figs. 23.1 and 23.3).

Patients have circulating anti-tissue transglutaminase and anti-endomysial antibodies, with the level of the latter correlating with degree of enteropathy; they can also develop other autoimmune disorders, in particular Hashimoto’s thyroiditis.

DDx: linear IgA bullous dermatosis, bullous pemphigoid, prurigo simplex, and bullous systemic lupus erythematosus; crusted lesions of the elbows are also seen in patients with Wegener’s granulomatosis and Churg–Strauss syndrome.

Rx: gluten-free diet (also reduces risk of enteropathy-associated T-cell lymphoma), dapsone (initially 25–50 mg per day after screening for glucose-6-phosphate dehydrogenase [G6PD] deficiency; average dose on a normal diet is 100 mg), and sulfapyridine; improvement of pruritus within a few days of instituting dapsone supports the diagnosis of DH.

Linear IgA Bullous Dermatosis (LABD)

Autoimmune bullous disease that occurs in both children and adults and can be drug-induced (Table 25.1); in children, it is sometimes referred to as ‘chronic bullous disease of childhood’.

Vesicles and bullae arise on the trunk and extremities and in children often favor the lower trunk and groin; lesions can assume a figurate arrangement and have been likened to a crown of jewels (Figs. 25.325.5).

Spontaneous remission in children, usually after 2–4 years; ~50% of adults have a spontaneous remission.

Histologically, a subepidermal bulla is accompanied by an infiltrate of neutrophils; by DIF, linear deposits of IgA are detected at the basement membrane zone of perilesional skin (see Figs. 23.1 and 23.3).

By indirect immunofluorescence (IIF), circulating IgA autoantibodies are detected in ~70% of patients with LABD (see Fig. 23.2); the autoantigen in LABD is a cleavage product of one of the two autoantigens of bullous pemphigoid (BP180; see Chapter 24).

DDx: bullous pemphigoid (linear deposits of IgG), DH (granular deposits of IgA), and mucous membrane (cicatricial) pemphigoid; for vancomycin-induced LABD, toxic epidermal necrolysis.

Important to review medications and withdraw possible culprits before instituting systemic therapy.

Rx: dapsone (often higher doses than for DH) or sulfapyridine, occasionally requiring the addition of prednisone; antibiotics (e.g. dicloxacillin, erythromycin, tetracycline) can be tried initially.

For further information see Ch. 31. From Dermatology, Third Edition.